Reaction

Dactylitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 969 reports · 52 co-occurring drugs

As of the last recalculation, Dactylitis appears in 969 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is METHYLPREDNISOLONE ACETATE (PRR 68.8).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Methylprednisolone Acetate	25	68.8	69.0
Sulfasalazine	192	65.5	65.6
Secukinumab	288	54.1	54.2
Esomeprazole Magnesium Capsule, Delayed Release	35	53.7	53.8
Esomeprazole Magnesium Delayed Release Capsules	35	53.7	53.8
Esomeprazole Magnesium Dihydrate	35	53.5	53.6
Diphenhydramine Hydrochloride Capsule, Liquid Filled	43	45.2	45.3
Tofacitinib Citrate	25	42.0	42.1
Leflunomide	165	40.6	40.7
Methotrexate Sodium	468	39.1	39.1
Adalimumab-Fkjp	77	38.7	38.8
Adalimumab-Aaty	77	37.9	37.9
Cetirizine Hydrochloride Allergy	50	37.3	37.4
Cetirizine Hydrochloride Tablets	50	37.3	37.4
Adalimumab-Adaz	83	36.9	36.9
Methotrexate	404	34.7	34.7
Meperidine Hydrochloride	14	33.1	33.2
Naproxen	100	30.4	30.4
Vitamin E	41	29.2	29.2
Duloxetine	64	21.1	21.1
Ixekizumab	34	20.4	20.4
Minocycline	10	18.6	18.6
Naproxen Sodium	108	18.1	18.2
Celecoxib	99	17.9	17.9
Tapentadol Hydrochloride	27	17.8	17.8
Desoximetasone	15	17.2	17.2
Esomeprazole	47	17.1	17.1
Rizatriptan Benzoate	8	17.0	17.0
Cetirizine	57	16.7	16.7
Diclofenac	60	15.9	15.9
Meloxicam	38	14.6	14.6
Hydroxychloroquine	47	14.2	14.2
Cetiirizine	27	14.1	14.1
Cannabidiol	15	14.0	14.0
Aripiprazole Oral	26	13.9	13.9
Aripiprazole Orally Disintegrating	26	13.9	13.9
Apremilast	84	13.4	13.4
Diclofenac Potassium, Film Coated	5	12.8	12.8
Diclofenac Potassium Tablets	5	12.8	12.8
Loperamide Hydrochloride Oral	6	12.7	12.7
Clobetasol Propionate Ointment Usp, 0.05%	6	12.6	12.6
Clobetasol Propionate	6	12.5	12.5
Diclofenac Potassium	6	12.0	12.0
Canakinumab	6	12.0	12.0
Golimumab	44	11.5	11.5
Ustekinumab	49	10.8	10.8
Tolvaptan	7	10.4	10.4
Certolizumab Pegol	52	10.0	10.0
Etanercept	214	9.6	9.6
Tofacitinib	71	8.8	8.8
Guselkumab	13	7.9	7.9
Bimekizumab	4	4.0	4.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.